Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adrenalone is a beta-ketoanalog of adrenaline, a small molecule that has been investigated for various pharmacological effects. It is currently being studied in a hydrogel-based drug delivery system for the treatment of chemotherapy-induced alopecia (CIA) due to its ability to induce cutaneous vasoconstriction. Historically, adrenalone has demonstrated radioprotective effects and has been explored for its potential in treating asthma and asthmatiform dyspneas. In research settings, it is utilized as an inhibitor of organic cation transporters (OCTs) and organic anion transporting polypeptides (OATPs) to study the hepatic uptake mechanisms of other drugs. It has also been shown to inhibit dopamine beta oxidase and norepinephrine synthesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Adrenalone.